During the past decade, Holy Cross Hospital, Hospital Pharmacy conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Holy Cross Hospital, Hospital Pharmacy" are "Follicular Lymphoma" (1 trials) and "Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Holy Cross Hospital, Hospital Pharmacy" in a lesser frequency.

Most popular intervention types in "Holy Cross Hospital, Hospital Pharmacy" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab-EU" (1 trials), "Bevacizumab-Pfizer" (1 trials), "Carboplatin" (1 trials), "MabThera®" (1 trials) and "PF-05280586" (1 trials). Other intervention names were less common.

The vast majority of trials in "Holy Cross Hospital, Hospital Pharmacy" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Holy Cross Hospital, Hospital Pharmacy". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Holy Cross Hospital, Hospital Pharmacy, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Holy Cross Hospital, Hospital Pharmacy, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".